Aldeyra Therapeutics opened lower at $0.65, compared with its previous close of $0.65. In the last trading session, the stock traded between $0.60 and $0.66. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Aldeyra Therapeutics is now worth
$ 6.98
Resulting in a loss of
$ 93.02 (93.02%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.03 (-4.05%)
Day High
$0.66
Day Low
$0.60
Day Open
$0.65
Prev Close
$0.65
Volume
5,12,982
1W Return
-3.99%
1M Return
-30.86%
3M Return
-58.75%
6M Return
-64.49%
1Y Return
-88.05%
Fundamentals
Market Cap ($ Mn)
38
PE Ratio
-
PB Ratio
2.36
PEG Ratio
-
ROE
-59.72%
ROCE
-56.17%
EPS (TTM)
$-0.06
Investment Returns
1 Week
-3.99%
1 Month
-30.86%
3 Months
-58.75%
6 Months
-64.49%
9 Months
-88.25%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
Aldeyra Therapeutics requests FDA transfer of ADX-2191 IND review
Aldeyra Therapeutics requested FDA transfer of ADX-2191 IND for PVRL to Division of Hematologic Malignancies. Company withdrew Special Protocol Assessment for ADX-2191 in PVRL. Initiation of SPA clinical trial for ADX-2191 in PVRL is not expected pending review. Regulatory path for ADX-2191 in PVRL is uncertain and may be delayed.
3 days ago
30Sep
Aldeyra Therapeutics shares rise 13.79% on FDA dispute plan
Aldeyra Therapeutics shares rose 13.79% to $1.32 following the announcement. Company plans formal dispute resolution request with the FDA. FDA previously issued Complete Response Letter citing lack of substantial evidence. Health Care sector down 0.51% over last 30 days, contrasting with stock rally. Only one of 11 market sectors advanced, indicating company-specific move.
1mo ago
16Jul
Aldeyra Therapeutics to seek FDA Type D meeting on Reproxalap NDA
Aldeyra Therapeutics disclosed in a SEC filing that it will request a Type D meeting with the FDA for the Reproxalap NDA resubmission by the end of Q3 2026.
4mo ago
10Jun
Aldeyra Therapeutics appoints Darlene Deptula-Hicks to board
Aldeyra Therapeutics appointed Darlene Deptula-Hicks to its board of directors, leveraging her over 30 years of experience in biotech finance and strategy. She currently serves as acting CFO of Normunity Inc. and formerly as CFO of F-star Therapeutics, Inc. The move supports Aldeyra's progress toward commercializing therapies for immune-mediated diseases.
